136 related articles for article (PubMed ID: 27393460)
1. Influence of sub-chronic selective 11β-hydroxysteroid dehydrogenase 1 inhibition on the hypothalamic-pituitary-adrenal axis in female cynomolgus monkeys.
Hamilton BS; Schoelch C; Schuler-Metz A; Krosky P; Lala DS; Claremon DA; McGeehan GM
Eur J Pharmacol; 2016 Oct; 789():68-74. PubMed ID: 27393460
[TBL] [Abstract][Full Text] [Related]
2. Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11β-hydroxysteroid dehydrogenase-1 (HSD1) inhibitor in humans: liver and adipose tissue 11β-HSD1 inhibition after acute and multiple administrations over 2 weeks.
Freude S; Heise T; Woerle HJ; Jungnik A; Rauch T; Hamilton B; Schölch C; Huang F; Graefe-Mody U
Diabetes Obes Metab; 2016 May; 18(5):483-90. PubMed ID: 26799632
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological characterization of the selective 11β-hydroxysteroid dehydrogenase 1 inhibitor, BI 135585, a clinical candidate for the treatment of type 2 diabetes.
Hamilton BS; Himmelsbach F; Nar H; Schuler-Metz A; Krosky P; Guo J; Guo R; Meng S; Zhao Y; Lala DS; Zhuang L; Claremon DA; McGeehan GM
Eur J Pharmacol; 2015 Jan; 746():50-5. PubMed ID: 25445047
[TBL] [Abstract][Full Text] [Related]
4. 11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation.
Cooper MS; Stewart PM
J Clin Endocrinol Metab; 2009 Dec; 94(12):4645-54. PubMed ID: 19837912
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers of hypothalamic-pituitary-adrenal axis activity in mice lacking 11β-HSD1 and H6PDH.
Abrahams L; Semjonous NM; Guest P; Zielinska A; Hughes B; Lavery GG; Stewart PM
J Endocrinol; 2012 Sep; 214(3):367-72. PubMed ID: 22718432
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor.
Ye XY; Chen SY; Wu S; Yoon DS; Wang H; Hong Z; O'Connor SP; Li J; Li JJ; Kennedy LJ; Walker SJ; Nayeem A; Sheriff S; Camac DM; Ramamurthy V; Morin PE; Zebo R; Taylor JR; Morgan NN; Ponticiello RP; Harrity T; Apedo A; Golla R; Seethala R; Wang M; Harper TW; Sleczka BG; He B; Kirby M; Leahy DK; Li J; Hanson RL; Guo Z; Li YX; DiMarco JD; Scaringe R; Maxwell B; Moulin F; Barrish JC; Gordon DA; Robl JA
J Med Chem; 2017 Jun; 60(12):4932-4948. PubMed ID: 28537398
[TBL] [Abstract][Full Text] [Related]
7. Liver-selective transgene rescue of hypothalamic-pituitary-adrenal axis dysfunction in 11beta-hydroxysteroid dehydrogenase type 1-deficient mice.
Paterson JM; Holmes MC; Kenyon CJ; Carter R; Mullins JJ; Seckl JR
Endocrinology; 2007 Mar; 148(3):961-6. PubMed ID: 17170103
[TBL] [Abstract][Full Text] [Related]
8. Intracellular regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase (11beta-HSD)-1 plays a key role in regulation of the hypothalamic-pituitary-adrenal axis: analysis of 11beta-HSD-1-deficient mice.
Harris HJ; Kotelevtsev Y; Mullins JJ; Seckl JR; Holmes MC
Endocrinology; 2001 Jan; 142(1):114-20. PubMed ID: 11145573
[TBL] [Abstract][Full Text] [Related]
9. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Stimson RH; Walker BR
Minerva Endocrinol; 2007 Sep; 32(3):141-59. PubMed ID: 17912154
[TBL] [Abstract][Full Text] [Related]
10. Will treating diabetes with 11β-HSD1 inhibitors affect the HPA axis?
Harno E; White A
Trends Endocrinol Metab; 2010 Oct; 21(10):619-27. PubMed ID: 20594868
[TBL] [Abstract][Full Text] [Related]
11. Discovery of BI 135585, an in vivo efficacious oxazinanone-based 11β hydroxysteroid dehydrogenase type 1 inhibitor.
Zhuang L; Tice CM; Xu Z; Zhao W; Cacatian S; Ye YJ; Singh SB; Lindblom P; McKeever BM; Krosky PM; Zhao Y; Lala D; Kruk BA; Meng S; Howard L; Johnson JA; Bukhtiyarov Y; Panemangalore R; Guo J; Guo R; Himmelsbach F; Hamilton B; Schuler-Metz A; Schauerte H; Gregg R; McGeehan GM; Leftheris K; Claremon DA
Bioorg Med Chem; 2017 Jul; 25(14):3649-3657. PubMed ID: 28528082
[TBL] [Abstract][Full Text] [Related]
12. Effects of menopause on hepatic 11β-hydroxysteroid dehydrogenase type 1 activity and adrenal sensitivity to adrenocorticotropin in healthy non-obese women.
Li S; Liu W; Wang L; Huang R; Chen Q; Wu Y; Cai Y
Gynecol Endocrinol; 2011 Oct; 27(10):794-9. PubMed ID: 21736538
[TBL] [Abstract][Full Text] [Related]
13. Vitamin A regulates hypothalamic-pituitary-adrenal axis status in LOU/C rats.
Marissal-Arvy N; Hamiani R; Richard E; Moisan MP; Pallet V
J Endocrinol; 2013 Oct; 219(1):21-7. PubMed ID: 23847298
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for the treatment of metabolic syndrome.
Wang M
Curr Opin Investig Drugs; 2006 Apr; 7(4):319-23. PubMed ID: 16625818
[TBL] [Abstract][Full Text] [Related]
15. Hypothalamic-pituitary-adrenal axis abnormalities in response to deletion of 11beta-HSD1 is strain-dependent.
Carter RN; Paterson JM; Tworowska U; Stenvers DJ; Mullins JJ; Seckl JR; Holmes MC
J Neuroendocrinol; 2009 Nov; 21(11):879-87. PubMed ID: 19602102
[TBL] [Abstract][Full Text] [Related]
16. Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor in the diet-induced obese mice.
Park JS; Rhee SD; Jung WH; Kang NS; Kim HY; Kang SK; Ahn JH; Kim KY
Eur J Pharmacol; 2012 Sep; 691(1-3):19-27. PubMed ID: 22760069
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy.
Wang M
Handb Exp Pharmacol; 2011; (203):127-46. PubMed ID: 21484570
[TBL] [Abstract][Full Text] [Related]
18. Is 11beta-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats.
Livingstone DE; Walker BR
J Pharmacol Exp Ther; 2003 Apr; 305(1):167-72. PubMed ID: 12649365
[TBL] [Abstract][Full Text] [Related]
19. Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease.
Walker BR; Andrew R
Ann N Y Acad Sci; 2006 Nov; 1083():165-84. PubMed ID: 17148739
[TBL] [Abstract][Full Text] [Related]
20. Alternative mechanism for anti-obesity effect of dehydroepiandrosterone: possible contribution of 11β-hydroxysteroid dehydrogenase type 1 inhibition in rodent adipose tissue.
Tagawa N; Minamitani E; Yamaguchi Y; Kobayashi Y
Steroids; 2011 Dec; 76(14):1546-53. PubMed ID: 21945397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]